financetom
Business
financetom
/
Business
/
Advent International expects good returns from Aditya Birla Capital investment in 3-5 years
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Advent International expects good returns from Aditya Birla Capital investment in 3-5 years
Sep 5, 2019 6:37 AM

US private equity group Advent International on Thursday said it expects good returns from Aditya Birla Capital Ltd (ABCL) investment in 3-5 years after the latter raised Rs 2,100 crore via preferential issue to marquee investors.

In an interview to CNBC-TV18's Nisha Poddar, Shweata Jalan, managing director, said, "The reason we liked ABCL was essentially the mix of businesses they have. ABCL's three largest businesses, non-banking financial companies (NBFC), insurance and asset management are fairly market-leading businesses. The way ABCL built their portfolio for NBFC business, we thought, it was fairly balanced."

"The combination of the parentage which prevents liquidity issues that they may have, the market position of the businesses, ability to create value and gain market share, we thought it is an asset," she said.

Jalan said Advent is exploring more options to invest in financial services companies, "We do believe it is a very opportune time. We will continue to look for more financial services opportunities and if we find something interesting and non-conflicting with some of the things that we have done, we would certainly look at it."

In terms of assessing the risk-reward ratio of ABCL, she further mentioned, "The wholesale book we felt was very clean and that is what we rollout our comfort from. In mutual funds, there are some exposures. However, you have to look at it on a scaled basis whether the value has been factored in at this point in time. When we are looking at some of those funds, then the answer was yes."

First Published:Sept 5, 2019 3:37 PM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Gogo Business Gets 25 STC Contracts for Gogo Galileo HDX System
Gogo Business Gets 25 STC Contracts for Gogo Galileo HDX System
Sep 26, 2024
10:30 AM EDT, 09/26/2024 (MT Newswires) -- Gogo ( GOGO ) said Thursday that Gogo Business Aviation has obtained 25 supplemental type certificate contracts for its Gogo Galileo HDX system, applicable to various business aircraft models. The contracts are expected to be completed in 2025 and encompass aircraft from super-light jets to ultra-long-range large-cabin models, including those from Bombardier, Embraer...
--Street Color: Chevron Agrees Hess CEO Will Not Join Chevron's Board Under FTC Deal, Bloomberg Reports
--Street Color: Chevron Agrees Hess CEO Will Not Join Chevron's Board Under FTC Deal, Bloomberg Reports
Sep 26, 2024
10:33 AM EDT, 09/26/2024 (MT Newswires) -- Price: 143.13, Change: -0.84, Percent Change: -0.58 ...
OpenAI departures from company not linked to restructuring, CEO says
OpenAI departures from company not linked to restructuring, CEO says
Sep 26, 2024
TURIN, Italy, Sept 26 (Reuters) - ChatGPT-maker OpenAI CEO Sam Altman said on Thursday the recent departure of top executives from the company had nothing to do with its planned restructuring. OpenAI's longtime chief technology officer Mira Murati abruptly announced her departure from the company on Wednesday. Greg Brockman, OpenAI's president, has also been on leave. On Wednesday Reuters reported...
Novo Nordisk And Evotec Collaborate On Stem Cell-Based Therapy Development
Novo Nordisk And Evotec Collaborate On Stem Cell-Based Therapy Development
Sep 26, 2024
On Thursday, Evotec SE ( EVO ) entered a technology development partnership with Novo Nordisk A/S ( NVO ) in cell therapy. Evotec and Novo Nordisk ( NVO ) have significant expertise and a strategic focus on supporting stem cell-based therapies. Also Read: German Drug Developer Evotec Seeks Adviser Input As Takeover Concerns Mount. To provide next-generation off-the-shelf cell therapy...
Copyright 2023-2026 - www.financetom.com All Rights Reserved